Characteristics of AML patients used in the study
| Patient number | FAB subtype | Cytogenetic | Mutations |
| 1 | Non-M3 | 48,XY,add(4)(p16),+8, der(16)del(16)(p13.1p13.3), del(16)(q22q24) | NC |
| 2 | M4E | 46,XX,inv(16)(p13.1q22) | NC |
| 3 | M1 | Normal karyotype 46,XY | FLT3-ITD positive |
| 4 | M4E | 46,XX,inv(16)(p13.3q22) | NC |
| 5 | M4E | 46,XY,inv(16) | NPM-1 negative |
| FLT-3 ITD negative | |||
| 6 | M5 | Normal karyotype 46,XX | NPM-1 positive |
| FLT-3 ITD positive | |||
| 7 | M1 | 46,XX, t(4;11) fusion transcripts (e10/e4 and e9/e5) | FLT3 ITD negative |
| Patient number | FAB subtype | Cytogenetic | Mutations |
| 1 | Non-M3 | 48,XY,add(4)(p16),+8, der(16)del(16)(p13.1p13.3), del(16)(q22q24) | NC |
| 2 | M4E | 46,XX,inv(16)(p13.1q22) | NC |
| 3 | M1 | Normal karyotype 46,XY | FLT3-ITD positive |
| 4 | M4E | 46,XX,inv(16)(p13.3q22) | NC |
| 5 | M4E | 46,XY,inv(16) | NPM-1 negative |
| FLT-3 ITD negative | |||
| 6 | M5 | Normal karyotype 46,XX | NPM-1 positive |
| FLT-3 ITD positive | |||
| 7 | M1 | 46,XX, t(4;11) fusion transcripts (e10/e4 and e9/e5) | FLT3 ITD negative |